Sheu SJ, et al. – The efficacy of ranibizumab was comprehensively explored, in persistent or recurrent diabetic macular edema (DME) after previous laser therapy. A beneficial effect was brought to light, of ranibizumab in DME patients who were previously treated with macular laser therapy. The response at week 12 was sustained up to 1 year. A suboptimal early visual response could speculate a long–term suboptimal response. It could also assist in determining patients who would benefit from an alternative regimen.